SCHEMBL24378128

SCHEMBL24378128

COC(=O)c1ccc2c(c1)NCC(C(N)=O)O2

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 1/20 0.47
HPGD P15428 3/20 0.46
KMT2A Q03164 2/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
HSD17B10 Q99714 4/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
SIRT1 Q96EB6 1/20 0.44
NISCH Q9Y2I1 1/20 0.42
CA12 O43570 2/20 0.41
CA9 Q16790 2/20 0.41
ALDH1A1 P00352 2/20 0.40
LMNA P02545 1/20 0.40
CYSLTR1 Q9Y271 1/20 0.40
MEN1 O00255 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
MAPT P10636 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18584331 0.90 ALOX5 (0.47) ALOX5HPGDKMT2ACYP1A2CYP3A4
SCHEMBL24378129 0.90 SIRT1 (0.44) ALOX5HPGDKMT2ACYP1A2CYP3A4
SCHEMBL18581139 0.84 ALOX5 (0.43) ALOX5HPGDKMT2ACYP1A2CYP3A4
SCHEMBL24378127 0.84 HSD17B10 (0.47) ALOX5HPGDKMT2ACYP1A2CYP3A4
SCHEMBL31751225 0.84 ALOX5 (0.49) ALOX5HPGDKMT2ACYP1A2CYP3A4
SCHEMBL34474927 0.83 ALOX5 (0.48) ALOX5HPGDKMT2ACYP1A2CYP3A4
SCHEMBL3932289 0.81 ALOX5 (0.46) ALOX5HPGDKMT2ACYP1A2CYP3A4
SCHEMBL18584333 0.79 HPGD (0.46) ALOX5HPGDKMT2ACYP1A2CYP3A4
SCHEMBL24997390 0.76 ADAMTS5 (0.49) HPGDKMT2ACYP1A2CYP3A4CYP2C9
SCHEMBL24377994 0.76 HPGD (0.45) HPGDKMT2ACYP1A2CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230399304-A1 COVALENT INHIBITORS OF CREATINE KINASE (CK) AND USES THEREOF FOR TREATING AND PREVENTING CANCER DANA-FARBER CANCER INSTITUTE, INC. 2023-12-14 US disclosed
US-20230399304-A1 COVALENT INHIBITORS OF CREATINE KINASE (CK) AND USES THEREOF FOR TREATING AND PREVENTING CANCER DANA-FARBER CANCER INSTITUTE, INC. 2023-12-14 US disclosed
WO-2022087433-A1 COVALENT INHIBITORS OF CREATINE KINASE (CK) AND USES THEREOF FOR TREATING AND PREVENTING CANCER DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230399304-A1 COVALENT INHIBITORS OF CREATINE KINASE (CK) AND USES THEREOF FOR TREATING AND PREVENTING CANCER CKMT1A; CKMT1B, PHKG1, PCK1 ALOX5 3231/4885HPGD 962/4885KMT2A 464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.